Efficiency of using cytoflavin in intensive therapy of premature neonates with cerebral ischemia
The efficiency of treating second-third degree cerebral ischemia with the metabolic neuroprotector Cytoflavin was analyzed in 48 premature neonatal infants within the framework of a multicenter randomized controlled comparative study. A study group consisted of 24 infants receiving cytoflavin, 2 ml/kg/day, in the first 5 days of life; 24 premature neonates from a control group had basic therapy. The used studies involved the evaluation of the neurological status, central and cerebral hemodynamic, and neurosonography. Psychomotor development was evaluated using the standardized INFANIB and BSID psychometric scales in infants at corrected age of months 1, 3, and 6. Cytoflavin was found to be well tolerated by premature neonates, it had no dangerous adverse reactions, exerted a systemic antihypoxant effect. The neuroprotective properties of the drug were supported by more successful psychomotor development rates within the first year of life in the study group infants than in the controls.